Response to Comments: MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma

This document (A59830) records responses to comments on MolDX LCD L39589 concerning molecular biomarker testing for risk stratification of cutaneous squamous cell carcinoma. It does not itself state coverage, indications, or limits; the LCD L39589 should be consulted for specific coverage criteria, coding, and documentation requirements. The notice period begins 07/04/2024 and the policy is effective 08/18/2024.

"This document is a response to public comments on MolDX LCD L39589 (Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma); refer to LCD L39589 for specific cover..."

Sign up to see full coverage criteria, indications, and limitations.